| __timestamp | Bristol-Myers Squibb Company | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 50829000 |
| Thursday, January 1, 2015 | 5001000000 | 57305000 |
| Friday, January 1, 2016 | 5002000000 | 116145000 |
| Sunday, January 1, 2017 | 4849000000 | 159362000 |
| Monday, January 1, 2018 | 4551000000 | 206366000 |
| Tuesday, January 1, 2019 | 4871000000 | 228244000 |
| Wednesday, January 1, 2020 | 7661000000 | 293355000 |
| Friday, January 1, 2021 | 7690000000 | 401715000 |
| Saturday, January 1, 2022 | 7814000000 | 459856000 |
| Sunday, January 1, 2023 | 7772000000 | 542705000 |
| Monday, January 1, 2024 | 8414000000 | 492128000 |
Unveiling the hidden dimensions of data
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of major players is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of Bristol-Myers Squibb Company and Exelixis, Inc. from 2014 to 2023. Bristol-Myers Squibb, a giant in the industry, consistently outspent Exelixis, with its SG&A expenses peaking in 2022 at approximately 7.8 billion dollars. This represents a 37% increase from its 2014 expenses. In contrast, Exelixis, a smaller biotech firm, saw its SG&A expenses grow by over 900% during the same period, reaching around 543 million dollars in 2023. This dramatic rise reflects Exelixis's aggressive expansion and investment in its operations. The data highlights the contrasting scales and growth strategies of these two companies, offering insights into their financial priorities and market positioning.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Exelixis, Inc.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Wave Life Sciences Ltd.
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and HUTCHMED (China) Limited
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.